Choose a country to view content specific to your location

Contact

Revogene® Carba C

The Revogene Carba C assay provides healthcare systems with a diagnostic solution to enable early detection and management of Carbapenem-Resistant Enterobacterales (CRE) from isolated colonies of Enterobacteriaceae, Acinetobacter baumannii, or Pseudomonas aeruginosa.

Catalog Number: 410500
Contact Sales
Support & Document

Why Revogene Carba C?

Carbapenem-Resistant Enterobacterales (CRE) infections are hazardous to our patients and alarming for healthcare systems. The CDC has deemed CRE an urgent public health threat that requires immediate and aggressive action. 1

Early identification and isolation of colonized or infected patients is key to limiting the spread of these organisms in healthcare settings and to help in better guidance of treatment.

1. https://www.cdc.gov/drugresistance/biggest_threats.html

  • sample_result_icon

    Efficient workflow – Sample to result in 3 easy steps

  • assay_flexibility_icon

    Detects and differentiates the 5 known gene sequences (PC, NDM, VIM, OXA-48-like, IMP) associated with carbapene resistance.

  • expansion_icon

    Platform for growth – Single analyte and multiplex testing capability

  • tech_icon2

    Helps respond quickly to the threat of carbapenemase-producing organisms by providing results in 70 min.

Early detection is key for CRE infection prevention and control. The CDC recommends “detecting and protecting” through early identification of CRE carriers, followed by prevention of transmission through implementation of infection control precautions.

CDC recommends “detecting and protecting”

Definitive answers, confidence in results

Contact Sales

FAQs

Revogene Carba C – 87150 x 5

References

1. https://www.cdc.gov/drugresistance/biggest_threats.html

2. https://www.cdc.gov/hai/organisms/cre/index.html

3. https://www.cdc.gov/hai/organisms/cre/cre-clinicianfaq.html

4. Neuner, E. & Gallagher J., 2017. Pharmacodynamic and pharmacokinetic considerations in the treatment of critically ill patients infected with carbapenem-resistant Enterobacteriaceae. Virulence. 8(4):440-452.

Pricing

To order, contact your regional sales representative or use the following contact information:
Contact Sales

Get in Touch With Us

Contact Us